The insider sales are routine post-exercise dispositions and do not signal management concern. Focus on the strong MYQORZO launch trajectory and upcoming PDUFA date (Nov 14, 2026) for MAPLE-HCM as key catalysts. Monitor next quarter's prescription growth and cash burn rate.
CYTK drugs
CYTK drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 6 $74.84entry
- T+1 · 6mo ago −0.73%α −0.40% · $74.29
- T+5 · 6mo ago −0.04%α −1.17% · $74.81
- T+20 · 6mo ago −5.52%α −8.30% · $70.71
- T+60 · 4mo ago +3.06%α +1.00% · $77.13
Price Chart
How similar events traded
Executive Summary
Two insiders at Cytokinetics sold a combined $2.39M in open-market stock on May 5, 2026, the same day the company reported strong Q1 2026 earnings highlighting a successful MYQORZO launch and positive ACACIA-HCM trial results. The sales represent ~0.03% of the $8.2B market cap, making them trivial in size and likely routine post-exercise dispositions rather than a bearish signal.
Key Financial Metrics
Key Facts
- Two insiders sold a total of $2.39M in open-market stock on May 5, 2026
- Sales represent ~0.03% of CYTK's $8.2B market cap
- Both sales were preceded by derivative exercises (non-cash or at low strike prices)
- Q1 2026 earnings reported same day: MYQORZO net product revenue of $4.8M, total revenue $19.4M vs $1.6M YoY
- ACACIA-HCM trial met dual primary endpoints in non-obstructive HCM
- Cash position $1.1B as of March 31, 2026
Financial Impact
Insider sales of $2.39M are immaterial relative to $8.2B market cap
Risk Factors
- Cash burn of $144M in Q1 2026 may require future capital raise
- Commercial execution risk as MYQORZO launch scales
- Regulatory risk ahead of MAPLE-HCM PDUFA date
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CYTK-1778012192019 |
Track record
46 reports on CYTK
7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $56.13 +4.41% settles Dec 15
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $56.13 +0.00% settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $56.13 −0.09% settles Dec 9
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $56.13 −0.09% settles Dec 9
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $56.13 +1.80% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $56.13 +1.80% settles Dec 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $56.13 +1.04% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $56.13 −11.75% settles Dec 3
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $56.13 −9.51% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers